Intralesional brentuximab vedotin for the treatment of primary cutaneous T‐cell lymphomas: a case series
International Journal of Dermatology · 2024-02 · 63 (2)
DOI: 10.1111/ijd.16979 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Dermatology, online erschienen am 13.12.2023. Verfasst von Jorge Arroyo-Andrés und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain. Hauptthemen laut MEDLINE: Immunoconjugates, Lymphoma, T-Cell, Cutaneous, Skin Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 5 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, 12 de Octubre University Hospital, Madrid, Spain.
- Pharmacy Department, 12 de Octubre University Hospital, Madrid, Spain.
ORCID-Profile: Jorge Arroyo-Andrés
Zitieren
APA
Arroyo-Andrés, J., Agud-Dios, M., Rubio-Muniz, C. A., Postigo, C., Cortijo-Cascajares, S., & Ortiz-Romero, P. L. (2024). Intralesional brentuximab vedotin for the treatment of primary cutaneous T‐cell lymphomas: a case series. International Journal of Dermatology, 63(2). https://doi.org/10.1111/ijd.16979
Vancouver
Arroyo-Andrés J, Agud-Dios M, Rubio-Muniz CA, Postigo C, Cortijo-Cascajares S, Ortiz-Romero PL. Intralesional brentuximab vedotin for the treatment of primary cutaneous T‐cell lymphomas: a case series. International Journal of Dermatology. 2024;63(2). doi:10.1111/ijd.16979
BibTeX
@article{ArroyoAndrs2024,
author = {Arroyo-Andrés, Jorge and Agud-Dios, Manuel and Rubio-Muniz, Carmen A and Postigo, Concepción and Cortijo-Cascajares, Susana and Ortiz-Romero, Pablo L},
title = {Intralesional brentuximab vedotin for the treatment of primary cutaneous T‐cell lymphomas: a case series},
journal = {International Journal of Dermatology},
year = {2024},
volume = {63},
number = {2},
doi = {10.1111/ijd.16979}
}
EUVIMED